Safer antibiotic dosing could protect kidneys in cystic fibrosis patients
NCT ID NCT02918409
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested two common IV antibiotics, tobramycin and colistin, in 51 adults with cystic fibrosis to find the safest and most effective way to treat lung infections. Researchers compared a new, less frequent dosing schedule for colistin to standard care, aiming to reduce kidney damage while still fighting the infection. The goal is to improve long-term treatment safety for people with cystic fibrosis.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Jewish Health
Denver, Colorado, 80206, United States